Madrigal Pharmaceuticals (MDGL) Interest Expenses (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Interest Expenses of $7.9 million for Q2 2026, up 140.61% year-over-year from $3.3 million in Q2 2025, and up 1.55% quarter-over-quarter from $7.8 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Interest Expenses (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Interest Expenses for 16 consecutive years, with $7.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest Expenses rose 140.61% year-over-year to $7.9 million; the TTM figure through Jun 2026 stood at $145.0 million (up 69965.7% YoY), while the FY2025 annual figure was $591.0 million, up 16.16% from the prior year.
- Interest Expenses advanced to $7.9 million in Q2 2026 per MDGL's latest filing, from $7.8 million in the prior quarter.
- Across five years, Interest Expenses topped out at $121.8 million in Q4 2025 and bottomed at -$10.1 million in Q4 2024.
- Historically, Interest Expenses has averaged $10.0 million across 5 years, with a median of $3.5 million in 2023.
- Annual changes were most pronounced in 2024 — Interest Expenses plunged 353.64% — and 2025, when it soared 1309.55%.
- Madrigal Pharmaceuticals' Interest Expenses stood at $1.7 million in 2022, then jumped by 136.09% to $4.0 million in 2023, then slumped by 353.64% to -$10.1 million in 2024, then jumped by 1309.55% to $121.8 million in 2025, then tumbled by 93.48% to $7.9 million in 2026.
- Business Quant data shows MDGL's Interest Expenses at $7.9 million in Q2 2026, $7.8 million in Q1 2026, and $121.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | 7.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.94 Mn |
| Jun 30, 2026 | 7.94 Mn |
| Mar 31, 2026 | 7.82 Mn |
| Mar 31, 2026 | 7.82 Mn |
| Dec 31, 2025 | 121.83 Mn |
| Dec 31, 2025 | 121.83 Mn |
| Sep 30, 2025 | 7.45 Mn |
| Sep 30, 2025 | 7.45 Mn |
| Jun 30, 2025 | 3.26 Mn |
| Jun 30, 2025 | 3.26 Mn |
| Mar 31, 2025 | 3.30 Mn |
| Mar 31, 2025 | 3.30 Mn |
| Dec 31, 2024 | 3.50 Mn |
| Dec 31, 2024 | 3.50 Mn |
| Sep 30, 2024 | 3.68 Mn |
| Sep 30, 2024 | 3.68 Mn |
| Jun 30, 2024 | 3.66 Mn |
| Jun 30, 2024 | 3.66 Mn |
| Mar 31, 2024 | 3.84 Mn |
| Mar 31, 2024 | 3.84 Mn |